Clinical-stage biopharmaceutical company MacroGenics has begun patient dosing in a Phase I dose expansion cohort trial of MGA271, an Fc-optimised monoclonal antibody that targets B7-H3-expressing tumour types.

The commencement of dosing triggered a $10m milestone payment to MacroGenics from its partner, Les Laboratoires Servier.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Expected to complete the trial in 2014, the study’s dose expansion portion will assess safety and pharmacokinetics at a weekly dose of 15mg/kg of MGA271, in addition to evaluating the potential anti-tumour activity.

“The study’s dose expansion portion will assess safety and pharmacokinetics at a weekly dose of 15mg/kg of MGA271, in addition to evaluating the potential anti-tumour activity.”

MacroGenics president and CEO Dr Scott Koenig said MGA271 has significant potential to treat a variety of solid tumours.

“We intend to assess and prioritise future indications for MGA271 clinical trials based on data from these dose expansion cohorts and determine the best path forward to potential approval and commercialisation,” Koenig said.

A total of 45 patients will be enrolled in the US within three cohort groups, two with specific tumour types of 15 patients each, and a third cohort composed of other B7-H3-expressing tumour types.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the fourth quarter of 2013, Servier plans to assess MGA271 in 45 additional cancer patients.

Around 26 patients representing 15 different types of tumours were enrolled in the dose escalation portion of the Phase I trial, while ten patients received additional cycles of MGA271 treatment and all have had stable disease at the first tumour re-assessment.

With no dose-limiting toxicity, mild or moderate infusion reactions were the most frequent adverse events in the trial.

Servier research and development president Dr Emmanuel Canet said, “The various product candidates included in our two alliances with MacroGenics, including MGA271 and three oncology DART programs, are advancing as we had hoped.”